SCHEMBL918787

SCHEMBL918787

COC(Cl)C(=O)Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11396493 0.75
SCHEMBL23415050 0.75
SCHEMBL2959573 0.75
SCHEMBL30096746 0.73
SCHEMBL2582323 0.73
SCHEMBL11801385 0.71
SCHEMBL28207988 0.71
SCHEMBL2579180 0.71
SCHEMBL4644783 0.71
SCHEMBL4629798 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11872202-B2 Pleuromutilin cinnamic acid ester compounds with activities against antibiotic-resistant infections SHAANXI UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) 2024-01-16 US disclosed
US-20230172889-A1 PLEUROMUTILIN CINNAMIC ACID ESTER COMPOUNDS WITH ACTIVITIES AGAINST ANTIBIOTIC-RESISTANT INFECTIONS SHAANXI UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) 2023-06-08 US disclosed
CN-105636933-A A method for preparing an intermediate of iopromide DAE WOONG PHARMA 2016-06-01 CN disclosed
US-8853230-B2 Inhibitors of JAK PORTOLA PHARMACEUTICALS, INC. (US) 2014-10-07 US disclosed
US-20130137673-A1 INHIBITORS OF JAK PORTOLA PHARMACEUTICALS, INC. (US) 2013-05-30 US disclosed
US-8367689-B2 Inhibitors of JAK PORTOLA PHARMACEUTICALS, INC. (US) 2013-02-05 US disclosed
US-20110005947-A1 INHIBITORS OF JAK PORTOLA PHARMACEUTICALS, INC. (US) 2011-01-13 US disclosed
WO-2010129802-A1 INHIBITORS OF JAK PORTOLA PHARMACEUTICALS, INC. (US) 2010-11-11 WO disclosed
US-20090221582-A1 Piperazine Derivatives And Their Use In Therapy VERNALIS (R&D) (GB) 2009-09-03 US disclosed
US-20090221582-A1 Piperazine Derivatives And Their Use In Therapy VERNALIS (R&D) (GB) 2009-09-03 US disclosed
WO-2007057687-A1 PIPERAZINE DERIVATIVES AND THEIR USE IN THERAPY VERNALIS (R & D) LIMITED (GB) 2007-05-24 WO disclosed
CN-1720047-A PgD2 receptor antagonists for the treatment of inflammatory diseases MILLENNIUM PHARM INC (US) 2006-01-11 CN disclosed
CN-1177029-A Process for trichromatic dyeing printing CIBA GEIGY AG (CH) 1998-03-25 CN disclosed